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Abstract
Introduction: In Belgium, breast cancer mortality has been monitored since 1954, whereas cancer incidence data
have only been made available for a few years. In this article we update historical trends of breast cancer mortality
and describe the recent breast cancer incidence.
Methods: Incidence data were extracted from the Belgium Cancer Registry from 2004 to 2006 for the Walloon and
Brussels Regions and Belgium, and from 1999 to 2006 for the Flemish Region. The Directorate-general Statistics and
Economic information provided the mortality data for the years 1954-1999 and 2004. The regional authorities of
the Flemish and Brussels Regions provided the mortality data for the years 2000-2003 and 2005-2006.
Results: In 2004, the World age-standardised breast cancer incidence for the whole of Belgium was 110 per 100,
000 person-years for all ages; and 172, 390 and 345 per 100, 000 person-years for the 35-49, 50-69, and 70+ age
groups, respectively. The incidence rate was slightly higher in each age group in the Brussels Region. In Flanders,
where the incidence could be observed during a longer period, an increase was observed until 2003 in the 50-69
age group, followed by a decrease. To the contrary, in the oldest age group, incidence continued to rise over the
whole period, whereas no change in incidence was observed between 1999 and 2006 in the 35-49 age group.
Mortality increased until the late 1980s and afterwards decreased in all regions and in age groups younger than 70.
In women of 70 years and older, the decline began later.
Conclusions: The burden of breast cancer in Belgium is very high. In 2004, Belgium ranked first for the age-
standardised incidence rate in Europe for all ages combined and in the 35-49 and 50-69 age groups. The impact of
the known risk factors and of mammographic screening should be further studied. The mortality rate in Belgium
ranked lower than incidence, suggesting favourable survival. Plausible explanations for the discrepancy between
incidence and mortality are discussed.
Introduction
Breast cancer incidence has shown a generalised
increase over the past century, with higher levels in
industrialised compared to non-industrialised countries
[1], mainly resulting from
major lifestyle changes favouring breast cancer, such
as lower parity, postponed childbearing, reduced breast
feeding, sedentariness, and obesity [2,3]. Since the last
decades of the 20th century, the use of hormonal repla-
cement therapy (HRT) by women entering menopause
contributed to the increase of the incidence [4,5]. At the
same time, the introduction of mammographic screen-
ing in women of about the same age has led to an
apparent increase in incidence because of earlier detec-
tion and some extent of overdiagnosis.
Before 2004, the International Agency for Research on
Cancer (IARC) estimates of breast cancer incidence in
Belgium [6] were based on incidence in neighbouring
countries adjusted for mortality in Belgium. These esti-
mates were very high, but no one knew whether this
statistical modelling reflected the reality. After an initial
period where cancer registration was only done in the
Flemish Region [7], the Belgian Cancer Registry has
been recently set up, producing real data [8], which fills
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a considerable gap in Europe. Recent comparisons
between countries made by the IARC with the true Bel-
gian data for 2005 indicate that Belgium belongs to the
countries with the highest incidence of breast cancer in
the world [9].
The age-adjusted mortality rate is a key indicator to
monitor the progress in breast cancer control [10,11]. In
contrast with the steady rise of incidence, the increase
in breast cancer mortality in most industrial countries
was interrupted in the late 1980s and was followed by a
flattening or even a decrease [1,12,13]. In this paper, we
update previous analyses on breast cancer mortality
trends [14] and compare rates between the Flemish,
Walloon and Brussels Regions for the period of which
regional data are available.
Belgian incidence and mortality rates by age groups




Belgium is a federal state divided into three regions (the
Flemish, Walloon and Brussels Regions), with a complex
distribution of healthcare organisation and data collec-
tion responsibilities. This results in asymmetric data
availability [15].
Incidence
A national Cancer Registry has been recently set up.
Methods of data collection have been described else-
where [16,17]. For this study we extracted breast cancer
incidence data from the Belgian Cancer Registry by year,
region and five-year age groups. Data are available from
1999 to 2006 for the Flemish Region and from 2004 to
2006 for the Brussels and Walloon Regions, and thus
for the whole country. Tumour pathological size (pT)
according to TNM Classifications 5 and 6 were also
extracted [18,19], with a proportional reallocation of the
pTx. The incidence data in the Flemish Region in 1999-
2002 were published by the IARC in “Cancer Incidence
in five continents” [20], which attests for a good level of
quality. The data for the whole country should be pub-
lished in the next edition.
Mortality
The Directorate-general Statistics and Economic infor-
mation (DGSEI), formerly known as the National Insti-
tute of Statistics (NIS-INS) [21] provided breast cancer
mortality data by calendar year and five-year age group
for the years 1954 until 1999 (included) and 2004 for
the whole country. Regional data were available for
1969-99 and 2004. The publication of mortality data in
the Walloon Region has run into delays, resulting in a
gap in available data for 2000-2003, the year 2005 being
in preparation at the time this report was written. The
mortality data from the Flemish and Brussels Region for
the years 2000-2003 and 2005-2006 were obtained
directly from the respective regional authorities [22,23].
Population
The midyear population data (females only) by year,
region, and five-year age group were computed from
data provided by the DGSEI.
Calculation and analysis
Crude rates (CR) were calculated by dividing the num-
ber of new cases in a given year by the total female
population in this year and expressed per 100, 000 per-
son-years. Age-standardised rates per 100, 000 person-
years (WSR) were calculated for incidence and mortality
using the world standard population [24]. Truncated
standardised rates as described by Jensen [25] were cal-
culated for three age groups, namely 35-49, 50-69 and
≥70 years of age.
The average incidence rates in the years 2004-2006 for
the three regions were compared by age group and pT.
We subsequently compared the Belgian age-standar-
dised breast cancer incidence and mortality rates of
2004, for all ages together and by age group, with those
published by Héry et al. [26] in 29 other European
countries in the period spanning 2000-2005 (depending
on the last available year). In Hery’s study, breast cancer
mortality data were extracted from the WHO mortality
database [27], which in July 2007 (date of last access)
did not yet include the 2004 mortality rates for Belgium,
and incidence data were extracted from volume VIII of
“Cancer Incidence in Five Continents” [28] and the
Eurocim Database [29]; which did not contain data for
Belgium. Age-standardised rates (WSR) were computed
in the article of Héry et al. for all ages and for the age
groups 35-49, 50-69 and ≥70. We completed those rates
with the Belgian rates and presented them graphically.
Trend analyses
Graphical presentation of trends
We plotted the standardised incidence and mortality
rates for all ages and each age group by calendar year
for the whole country. At the level of the regions, mor-
tality rates were aggregated by five-year periods in order
to smooth out the variability due to the small numbers.
We also plotted the age-specific mortality rates by
birth cohorts. The birth cohorts include women born in
the same period so they have been exposed to common
risk factors throughout their lives at the same age. This
way of presenting the data can give insights into phe-
nomena affecting specific generations. Cohorts are
defined by subtracting the first year of each five-year
age category from the first year of each five-year period
around the death date. Since the age groups and the
calendar periods both span five years, the birth cohorts
are ten years wide. Successive birth cohorts overlap
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partly and are usually indicated by their central year
[30,31].
Join point analysis
Temporal patterns of rates across different time periods
for each age group were analysed by calculating annual
percentage changes (APCs) and the 95% confidence
intervals (95% CIs) for the disease rates, with log-linear
Poisson models, using “join points”. This method, as
well as a computer software, were developed by the US
National Cancer Institute [32,33], and have been used in
several studies to identify temporal patterns in death
rates [12,34]. We used the Join Point Regression Soft-
ware, version 3.4.3 [35].
Results
Breast cancer incidence
The absolute numbers, the crude and age-standardised
incidence rates by region and age group are presented
in Table 1 for the available years. The age-standardised
rates varied between 153 and 198 per 100, 000
women-year in the 35 to 49 years age group, between
322 and 437 per 100, 000 in women aged 50-69 years,
and between 325 and 417 per 100, 000 in the oldest
group.
Regional differences
The age-standardised incidence rate in 2004-2006 was
10-12% higher in Brussels than in the Flemish Region
for all age groups (Table 1). The rate in the Walloon
region was intermediate, except for the oldest age
group, where it was equal to that in the Flemish Region.
After proportional reallocation of the pTx (unknown
tumour sizes), the incidence of pT1 tumours was high-
est in Brussels (77 per 100, 000), versus 72 per 100, 000
in Wallonia and 62 per 100, 000 in the Flemish Region
(Figure 1).
Among the tumours with a known pT category, the
proportion of small size tumours (pT1) was slightly
higher in Brussels (62.8%) than in Wallonia (60.5%) and
in Flanders (56.4%). The proportion of more advanced
tumours was quite similar between the regions.
Time trends
Eight consecutive years of incidence data are currently
available for the Flemish Region (Figure 2). While a
quite stable incidence rate was observed in the preme-
nopausal group (35-49 years), two phases were distin-
guished in women aged 50-69 years: a first increase
from 1999-2003 (APC = 5.4%) and then a sharp
decrease from 2003 to 2006 (APC = -4%). In the oldest
age group, a steady increase was observed over the
whole period (APC = 1.5%).
Comparison with twenty-four other European countries in
2000-2005
Figure 3 shows the age-standardised incidence rates
(WSR) for Belgium and twenty-four other European
countries sorted by decreasing incidence in 2000-2005,
(depending on the last available data). Rates for the
other countries were published by Héry et al [36]. The
range of incidence within all the countries was 39-110
per 100, 000 women-years. Belgium ranked first for all
ages together, with an incidence rate of 110 per 100,
000. This is 42% above the median rate, and 19% above
the second ranking country (Switzerland). In the 35-49
year age group the rate was 172 per 100, 000; this was
54% higher than the median rate and 22% higher than
the second country (The Netherlands). In the 50-69 year
age group the rate was 380 per 100, 000, which was 39%
higher than the median and 17% higher than the second
country (Switzerland). In the age group 70+, Belgium
ranked fifth with a rate of 345 per 100, 000, which was
21% above the median rate.
Breast cancer mortality trends
Whole of Belgium
All ages
Figure 4 shows the observed and fitted mortality rates in
Belgium from 1954 to 1999 and for 2004. A first break
point can be identified in 1986 [1980-1989] and a sec-
ond one in 1996 [1993-1998]. The annual percentage
changes (APC) were respectively 0.98% [0.9%-1.1%],
-0.5% [-1.3%;0.2%] and -2.6% [-3.6%;-1.5%] for the peri-
ods 1954-1986, 1986-1996, and 1996-2004.
Changes in mortality rates by age group, Belgium
A similar trend can be observed in the three age groups,
with an initial increase followed by a marked decrease
in mortality rates (Table 2).
The breakpoint was 1986 [1983-1991] for younger
women, 1988 [1986-1991] for women aged 50-69, and
1994 [1992-1996] for older women. The annual percen-
tage of change in the second period was larger for the
youngest women (NS).
Changes in age-specific mortality rates by period and
birth cohort, Belgium
Figure 5 shows the changes in the age-specific mortality
rates in the successive birth cohorts. With the exception
of the oldest women, for whom the increase is quite
continuous, one can see sharp increases in the age-spe-
cific mortality rates for the cohorts of women born in
the first decade of the 20th century (midpoints 1900 and
1905). After this continuously increasing mortality rate
in successive cohorts born in the late 19th and the first
decades of the 20th century, we discern a stabilisation or
decrease that starts for older age groups in cohorts born
earlier, indicating rather a period-effect situated near
1985. For instance, the change in the brown curve,
which represents the women aged 55-59, occurs for the
cohort born in 1930 [1925-1934], indicating something
that occurred around the calendar period 1985-1989;
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the change in the blue curve, which represents the
women aged 55-59, occurs for the cohort born in 1920
[1915-1924], indicating something occurring in the same
calendar period 1985-1989.
Mortality by region
The age-standardised mortality rate was lower in Wallo-
nia than in the two other regions for all ages together
and in women above 50 but not in younger women
(Figure 6).
The mortality rates in Brussels and Flanders decreased
since the period 1985-1990, while they remained stable
in Wallonia. However, it must be noted that no recent
data were available for this region.
The decrease in the mortality rate in young women
began earlier in Brussels than in the other regions.
Breast cancer mortality in Belgium compared with other
European countries in 2001-2004
Figure 7 shows the standardised mortality rates for
thirty European countries in the years 2001-2004
(depending on the last available data).
The mortality rates in these countries range from 13.9
per 100, 000 in Spain to 24.8 per 100, 000 in Denmark.
Table 1 Breast cancer incidence by region and age group, Belgium, 1999-2006
Flemish Region Walloon Region Brussels Region Belgium
Year Age N CR WSR N CR WSR N CR WSR N CR WSR
1999 35-49 1014 153, 4 158, 2 NA NA NA NA NA NA NA NA NA
50-69 2247 332, 0 332, 4 NA NA NA NA NA NA NA NA NA
70+ 1293 318, 7 325, 8 NA NA NA NA NA NA NA NA NA
all ages 4676 155, 5 98, 4 NA NA NA NA NA NA NA NA NA
2000 35-49 1060 158, 5 163, 2 NA NA NA NA NA NA NA NA NA
50-69 2398 352, 4 353, 2 NA NA NA NA NA NA NA NA NA
70+ 1341 323, 4 322, 0 NA NA NA NA NA NA NA NA NA
all ages 4909 162, 9 102, 5 NA NA NA NA NA NA NA NA NA
2001 35-49 1157 171, 3 174, 9 NA NA NA NA NA NA NA NA NA
50-69 2671 390, 8 388, 4 NA NA NA NA NA NA NA NA NA
70+ 1411 332, 2 333, 7 NA NA NA NA NA NA NA NA NA
all ages 5341 176, 7 110, 3 NA NA NA NA NA NA NA NA NA
2002 35-49 1029 151, 2 153, 3 NA NA NA NA NA NA NA NA NA
50-69 2751 400, 2 398, 7 NA NA NA NA NA NA NA NA NA
70+ 1394 320, 8 319, 6 NA NA NA NA NA NA NA NA NA
all ages 5280 174, 1 107, 4 NA NA NA NA NA NA NA NA NA
2003 35-49 1146 167, 5 169, 4 NA NA NA NA NA NA NA NA NA
50-69 2825 407, 5 406, 7 NA NA NA NA NA NA NA NA NA
70+ 1493 337, 3 336, 5 NA NA NA NA NA NA NA NA NA
all ages 5572 183, 0 112, 6 NA NA NA NA NA NA NA NA NA
2004 35-49 1128 164, 6 165, 9 672 179, 0 178, 9 194 184, 0 189, 8 1994 171, 0 172, 1
50-69 2583 370, 8 370, 8 1577 414, 6 413, 8 439 436, 6 437, 1 4599 390, 5 390, 2
70+ 1540 345, 2 342, 1 884 339, 3 342, 9 276 362, 8 376, 9 2700 344, 9 345, 0
all ages 5339 175, 1 105, 9 3178 182, 6 114, 8 928 178, 6 122, 2 9445 177, 9 110, 2
2005 35-49 1178 171, 5 171, 2 647 172, 3 170, 9 202 190, 0 193, 7 2027 173, 4 173, 2
50-69 2574 365, 1 364, 4 1434 370, 8 374, 4 365 360, 3 358, 9 4373 366, 6 366, 9
70+ 1639 360, 5 354, 1 928 353, 7 353, 8 288 382, 6 395, 1 2855 360, 4 357, 1
all ages 5500 179, 5 107, 0 3061 175, 1 107, 9 870 166, 3 110, 3 9431 176, 8 107, 5
2006 35-49 1158 168, 3 167, 0 649 172, 7 171, 3 198 184, 0 189, 5 2005 171, 1 170, 4
50-69 2570 359, 4 360, 2 1459 370, 5 375, 2 419 410, 3 408, 6 4448 367, 3 368, 8
70+ 1684 364, 6 361, 2 883 335, 8 342, 6 296 396, 7 417, 4 2863 358, 1 359, 6
all ages 5511 178, 9 105, 5 3045 173, 3 107, 9 933 176, 3 119, 2 9489 176, 8 107, 4
35-49 168, 1 168, 1 174, 7 173, 7 186, 0 191, 0 171, 8 171, 9
average rates 50-69 365, 0 365, 1 385, 0 387, 5 402, 3 401, 5 374, 7 375, 2
2004-2006 70+ 356, 9 352, 5 342, 9 346, 5 380, 6 396, 2 354, 5 353, 9
all ages 177, 8 106, 1 177, 0 110, 2 173, 7 117, 2 177, 2 108, 3
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Belgium ranks fifth for all ages together, with a mortality
rate of 20.5 per 100, 000. In the 35-49 age group, the
Belgian rate was sixth at 19.9 per 100, 000. In the 50-69
age group the Belgian rate was fifth at 68.0 per 100.000,
while in the 70+ age group the Belgian rate was eighth
at 142.6 per 100, 000.
Discussion
This study integrates all available mortality and inci-
dence data in order to describe the current burden and
the trends of breast cancer in Belgium. The incidence
rate in Belgium is the highest in Europe, whereas the
mortality rate ranks fifth. The mortality rate has
declined in all age groups and all regions since the late
1980s, whereas the incidence seems to have continued
to increase until 2003, and then stabilised and even
decreased in the post-menopausal age group (50-69
years).
Strengths and limitations of the study
In Belgium, mortality data have been available for more
than fifty years. Still, the cause of death reported in
mortality statistics can be of limited reliability. However,
while the quality of the data on causes of death in Bel-
gium is considered moderate by the WHO [37], the cer-
tification of deaths specifically attributed to breast
cancer is considered rather reliable.
The very high rate of incidence could suggest a regis-
tration bias. Indeed, the new Cancer Registry has only
recently started to register cancer cases in the Brussels
and Walloon regions. During the first years of registra-
tion, it is likely that some prevalent cases are included
as incident cases. Therefore, all the available pathology
lab reports for the years 2004-2006 were carefully
reviewed by the Cancer Registry’s staff and the inclusion
of prevalent or unconfirmed cases was estimated to be
less than 3%. Moreover, the use of an unambiguous
identifier in the registration of cancer cases (the national
identification number used by the social security admin-
istration) avoids duplicate registration of the same
patient. Therefore, over-registration can be considered
limited.
A long-term trend analysis could only be performed
for mortality, since there were no reliable incidence data
before 1999 for the Flemish Region and before 2004 for
the Walloon and Brussels Region.
At this stage, we limited the cohort analysis to a gra-
phical presentation and did not perform age-cohort-per-
iod (ACP) modelling of the mortality trends. A prior
ACP analysis identified a significant increasing cohort
effect for post-menopausal women (≥50 years) for gen-
erations born between 1900 and 1925 (slope: 1.2%, 95%
CI: 0.6-1.9%), whereas the effect was less clear in preme-
nopausal women (slope: -1.0%; 95% CI: -1.6; -0.4%) [14].
This model should be updated with the new available
mortality data.
Current state of incidence and mortality rates
The incidence rate of breast cancer in Belgium in 2004
was the highest in Europe, for all ages together and for
the 35-49 and 50-69 age groups. The excess of incidence
was 42% above the median rate, and 19% above the rate
of the 2nd ranking country (Switzerland). However, at
the same time, the mortality rate ranked fifth in Europe,
being situated in the highest quartile of the European
rates.
The very high incidence rate is most likely the result
of several risk factors and interventions. As we explained
in the introduction, decline in fertility, postponing child-
bearing and use of HRT are all associated with a true
increase of breast cancer risk, while mammographic
screening only induces an apparent rise in the incidence
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Figure 1 Rate of breast cancer according to the pathological T
categories (pT*) by region, Belgium, 2004-2006. *The pTx
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Figure 2 Evolution of breast cancer incidence by age group,
Flemish Region (Belgium, 1999-2006). Age-standardised
incidence rate (WSR) per 100, 000 women-years.
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declined continuously in the second half of the 20th cen-
tury in all European countries and the USA. In Belgium,
the overall fertility rate fell from 2.6 children per
woman in 1965 to 1.5 in 1985. From 1975 to 1995, the
Belgian fertility index was quite low among EU 15 coun-
tries [38]. Childbearing has also been postponed, with
the peak shifting from 24 years to 29 years between
1965 and 2000 [39]. The use of HRT is another risk fac-
tor for breast cancer. In Flanders, it was estimated to
reach 20% in women of 50-69 years in 2001 [40], and
could even have been higher in the other regions [41].
In The Netherlands, the rate of HRT use in menopausal
women was only 13% in 1997 [42], while in France it
was estimated to be 28% [43]. To our knowledge, no
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Figure 3 Breast cancer incidence by age group in 2000-2005 in 25 European countries. Age-standardised rate (WSR) for all ages (top left),
35-49 years (top right), 50-69 (bottom left) and 70 + (bottom right). Belgian rates are coloured red. Adapted from Hery et al. [36].
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systematic comparison of the percentage and the type of
HRT use in the European countries has been done yet,
and this could be a topic for further study. The attribu-
table fraction of the breast cancer incidence in the 50-
69 years age group due to HRT use in Flanders has
been put at 11% for the cancers diagnosed in 2003 [40].
The aggressiveness of HRT-induced tumours is still con-
troversial, with old studies showing a higher proportion
of localised tumours and more favourable biological fea-
tures in women having had HRT [44,45], whereas a
recent publication on the follow-up of the women
included in the WHI study rather suggests that HRT-
related tumours are more aggressive [46].
Mammographic screening produces an apparent
increase in the incidence in at least two ways, namely,
an advance in diagnosis (lead time bias), and the detec-
tion of slowly or non-progressive tumours, that would
never have surfaced clinically (over-diagnosis) [47]. In
Belgium, some opportunistic (as opposed to organised)
mammographic screening began in the late 1980s, but
its coverage achieved only 38% in 1999-2000. A nation-
wide organised screening programme was set up in
2001, while some opportunistic screening continued
besides it. The overall mammographic coverage (defined
as the proportion of women aged 50-69 having had a
mammography over the last two years) was 59% in
2005-2006, with 28% in organised and 31% in opportu-
nistic screening [48]. Although this coverage is not that
high, it can lead to an inflated detection rate if screening
sensitivity is very high.
Information on historical changes in the prevalence of
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Figure 4 Breast cancer mortality by age group, Belgium, 1954-
2006. Observed (points) and fitted (lines) age-standardised mortality
rates (WSR) per 100, 000 women-years in the three age groups 35-
49, 50-69, and ≥70 years, respectively.
Table 2 Join points and annual percentage changes
(APC) in mortality rates and corresponding confidence
intervals (CI) in each period by age group, Belgium 1954-
2004
Age group Period Join points [CI] APC [CI]
All ages 1954-1986 1986 [1980-1989] 0.98 * [0.9;1.1]
1986-1996 1996 [1993-1998] - 0.5 [-1.3;0.2]
1996-2004 / - 2.6* [-3.6;-1.5]
35-49 years 1954-1986 1986 [1983 - 1991] 0.7%* [0.5-1.0]
1986-2004 / -2.2%* [-3.0; -1.5]
50-69 years 1954-1988 1988 [1986 - 1991] 1.2%* [1.0; 1.4]
1988-2004 / -1.3%* [-2.0; -0.7]
> = 70 years 1954-1994 1994 [1992-1996] 0.8%* [0.7; 0.9]
1994-2004 / -1.4%* [-2.2; -0.5]
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Figure 5 Age-specific breast cancer mortality rates in the
successive birth cohorts (1870-1950), Belgium.
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Figure 6 Standardised mortality rate trends by region, for all
ages (upper left), 35-49 years (upper right), 50-69 years
(bottom left) and > = 70 (bottom right).
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not available. Moreover, a large number of the etiologi-
cal factors of breast cancer remain unknown.
The discrepancy between the incidence and mortality
rankings suggests that some part of the excess in inci-
dence is due to weakly aggressive tumours. This could
reflect some inflation of the incidence due to the screen-
ing, since screening tends to detect some small tumours
with low potential of malignancy. Since over-diagnosing
small and indolent tumours can affect women’s quality
of life, with no impact on the mortality, there is a real
need to evaluate accurately the performance indicators
of both organised and opportunistic screening.
Further research should focus on estimation of the
attributable fraction of all known risk factors, including
a comparison between countries where information on
risk factors, screening and cancer treatment is available.
The incidence rate was higher in all age groups in
Brussels than in the other two regions, with a more
All 
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Figure 7 Breast cancer mortality by age group in 2001-2004 in 30 European countries. Age-standardised rate (WSR) for all ages (top left),
35-49 years (top right), 50-69 years (bottom left) and 70+ (bottom right). Belgian rates are coloured red. Adapted from Hery et al. [36].
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favourable distribution of the stages in Brussels than in
the Flemish Region. Indeed, while the overall coverage
of screening was quite similar between the regions, the
distribution of the type of screening was very different
between them, with a ratio organised/opportunistic
screening of 2.0, 0.2 and 0.2 respectively in the Flemish,
Brussels and Walloon regions. The hypothesis of having
some degree of overdiagnosis in Brussels should be
examined. In any event, caution is needed in interpret-
ing the observed differences in the stage distribution,
since about 20% of the stages remain unknown.
Trends
As in many other countries [12], we observe a strong
increase in the mortality rates until the end of the
1980s, followed by a decline. The period of increase
(1954-1986) definitely reflects an increase in incidence,
since an increase in case-fatality rate over time seems
very unlikely. The subsequent decline in mortality (after
1986) most probably corresponds to an improvement in
survival rather than a decrease in incidence, as many
risk factors of incidence continued to increase until the
end of the century. An improvement in survival could
result from several causes, such as better treatments
(use of oestrogen-antagonists, better chemotherapeutic
schemes, introduction of guidelines, and adherence to
these guidelines), earlier diagnosis with down-staging
resulting from an increased awareness of the disease
and the possibilities of treatment, and mammographic
screening. The decline in breast cancer mortality started
before the implementation of nationwide breast cancer
screening (2001) and also reached unscreened age
groups; the screening probably cannot be expected to
have a mortality-reducing effect before the end of the
first decade of 2000, and its relative contribution to the
decline in mortality observed since 1986 is likely to be
low.
The decrease in mortality rates in older women was
observed later, suggesting less efficient treatment
schemes in this age group. This could also be explained
by a delay in the mortality of women in younger age
groups.
The birth-cohort analysis shows a peak in mortality
for the women born between the years 1905 and 1920
suggesting a major change in the reproductive pattern at
this time. This finding should be further studied.
The incidence figures could be followed for an 8-year
period in the Flemish Region; a two-phase pattern was
clearly observed in the 50-69-year-old, with a sharp
increase until 2003 followed by a decrease. This phe-
nomenon was interpreted as resulting from a drastic
decline in HRT use [40] resulting from the publication
of two large studies showing the role of those hormones
in the development of breast cancer [4,5]. Similar
declines in breast cancer and HRT use have been
described in many other countries [43,49-52].
Conclusions and recommendations
Both the incidence and mortality of breast cancer in
Belgium are high, confirming breast cancer as a serious
public health problem. The high incidence of breast
cancer in Belgium results from a combination of fac-
tors, such as low fertility indices and high use of HRT,
coinciding with screening effects. However, the large
excess of incidence compared with the rest of Europe
is not translated to mortality, where Belgium occupies
the 5th place in Europe. Plausible explanations for the
discrepancy between incidence and mortality rankings
can be effectiveness of treatment, and an inflation of
the number of weakly aggressive tumours detected by
screening.
It should be investigated whether differences in
screening strategies could explain the regional variation
in incidence.
The decreasing trend in mortality since the mid-1980s
comes too early to be attributed to screening and is
mostly due to improved treatment, improved access to
treatment, and a better awareness of the disease.
Because they contribute to evaluating health policies,
statistics on causes of death are invaluable. Filling in the
gaps in the publication of Wallonia’s mortality statistics
is indispensable.
The high incidence of breast cancer in Belgium
requires further research using analytical epidemiologi-
cal methods involving individual data. This research
should focus on an accurate evaluation of all the screen-
ing strategies applied (opportunistic and organised) as
well as calculation of the attributable fraction of all
known risk factors in Belgium and modelling of the dif-
ferent risk factors in Europe.
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